1. Home
  2. WLDS vs XCUR Comparison

WLDS vs XCUR Comparison

Compare WLDS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wearable Devices Ltd.

WLDS

Wearable Devices Ltd.

BUY

Current Price

$1.39

Market Cap

7.7M

ML Signal

BUY

Logo Exicure Inc.

XCUR

Exicure Inc.

HOLD

Current Price

$1.13

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLDS
XCUR
Founded
2014
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
9.2M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
WLDS
XCUR
Price
$1.39
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 201.0K
19.3K
Earning Date
08-24-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 83.37
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.02
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.63
$0.94
52 Week High
$6.50
$9.48

Technical Indicators

Market Signals
Indicator
WLDS
XCUR
Relative Strength Index (RSI) 44.82 47.15
Support Level $1.30 $0.99
Resistance Level $1.51 $1.48
Average True Range (ATR) 0.10 0.12
MACD 0.03 0.00
Stochastic Oscillator 69.44 49.18

Price Performance

Historical Comparison
WLDS
XCUR

About WLDS Wearable Devices Ltd.

Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: